1 Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge , Cambridge, United Kingdom .
2 Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust , Cambridge, United Kingdom .
Diabetes Technol Ther. 2018 Jul;20(7):501-505. doi: 10.1089/dia.2018.0060.
Tight glucose control during labor and delivery is recommended for pregnant women with type 1 diabetes. This can be challenging to achieve using the current treatment modalities. The automated nature of closed loop and its ability to adapt to real-time glucose levels make it well suited for use during labor, delivery, and the immediate postpartum period. We report observational data of participants from two randomized crossover trials who chose to continue using closed loop during labor, delivery, and postpartum. Labor was defined as the 24 h before delivery and postpartum as the 48 h after delivery. The glucose target range during pregnancy was 3.5-7.8 mmol/L (63-140 mg/dL) and 3.9-10 mmol/L (70-180 mg/dL) after delivery. Twenty-seven (84.4%) of the potential 32 trial participants used closed loop through labor, delivery, and postpartum. Use of closed loop was associated with 82.0% (interquartile range [IQR] 49.3, 93.0) time-in-target range during labor and delivery and a mean glucose of 6.9 ± 1.4 mmol/L (124 ± 25 mg/dL). Closed loop performed well throughout vaginal, elective, and emergency cesarean section deliveries. Postpartum, women spent 83.3% (IQR 75.2, 94.6) time-in-target range (3.9-10.0 mmol/L [70-180 mg/dL]), with a mean glucose of 7.2 ± 1.4 mmol/L (130 ± 25 mg/dL). There was no difference in maternal glucose concentration between mothers of infants with and without neonatal hypoglycemia (6.9 ± 1.6 mmol/L and 6.8 ± 1.1 mmol/L [124 ± 29 mg/dL and 122 ± 20 mg/dL] respectively; P = 0.84). Automated closed-loop insulin delivery is feasible during hospital admissions for labor, delivery, and postpartum. Larger scale studies are needed to evaluate its efficacy compared with current clinical approaches as well as understand how women and healthcare providers will adopt this technology.
对于患有 1 型糖尿病的孕妇,建议在分娩和分娩期间进行严格的血糖控制。使用当前的治疗方式可能具有挑战性。闭环的自动化性质及其适应实时血糖水平的能力使其非常适合在分娩、分娩和产后立即使用。我们报告了两项随机交叉试验参与者的观察数据,这些参与者选择在分娩、分娩和产后继续使用闭环。分娩定义为分娩前 24 小时,产后为分娩后 48 小时。怀孕期间的血糖目标范围为 3.5-7.8mmol/L(63-140mg/dL),分娩后为 3.9-10mmol/L(70-180mg/dL)。在潜在的 32 名试验参与者中,有 27 名(84.4%)在分娩、分娩和产后期间使用了闭环。使用闭环与分娩和分娩期间 82.0%(IQR 49.3,93.0)的目标范围内时间相关,平均血糖为 6.9±1.4mmol/L(124±25mg/dL)。闭环在阴道、选择性和紧急剖宫产分娩中表现良好。产后,女性 83.3%(IQR 75.2,94.6)的时间在目标范围内(3.9-10.0mmol/L [70-180mg/dL]),平均血糖为 7.2±1.4mmol/L(130±25mg/dL)。新生儿低血糖和无新生儿低血糖的母亲之间的血糖浓度没有差异(分别为 6.9±1.6mmol/L 和 6.8±1.1mmol/L[124±29mg/dL 和 122±20mg/dL];P=0.84)。在因分娩、分娩和产后住院期间,自动闭环胰岛素输送是可行的。需要更大规模的研究来评估其与当前临床方法相比的疗效,以及了解女性和医疗保健提供者将如何采用这项技术。